<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Chemokine CCL5/RANTES is highly expressed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> where it contributes to <z:mp ids='MP_0001845'>inflammation</z:mp> and malignant progression </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we show that CCL5 plays a critical role in immune escape in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We found that higher levels of CCL5 expression in human and murine <z:e sem="disease" ids="C0009375" disease_type="Neoplastic Process" abbrv="">colon tumor</z:e> cells correlated with higher levels of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of CD8+ T cells and infiltration of T-regulatory cells (T(reg)) </plain></SENT>
<SENT sid="3" pm="."><plain>In mouse cells, <z:chebi fb="40" ids="33697">RNA</z:chebi> interference (RNAi)-mediated knockdown of CCL5 delayed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in immunocompetent syngeneic hosts but had no effect on <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in immunodeficient hosts </plain></SENT>
<SENT sid="4" pm="."><plain>Reduced <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> was correlated with a reduction in T(reg) infiltration and CD8(+) T-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, we found that CCL5 enhanced the cytotoxicity of T(reg) against CD8(+) T cells </plain></SENT>
<SENT sid="6" pm="."><plain>We also found <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> to be diminished in mice lacking CCR5, a CCL5 receptor, where a similar decrease in both T(reg) cell infiltration and CD8(+) T-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was noted </plain></SENT>
<SENT sid="7" pm="."><plain>TGF-β signaling blockade diminished <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of CD8(+) T cells, implicating TGF-β as an effector of CCL5 action </plain></SENT>
<SENT sid="8" pm="."><plain>In support of this concept, CCL5 failed to enhance the production of TGF-β by CCR5-deficient T(reg) or to enhance their cytotoxic effects against CD8(+) T cells </plain></SENT>
<SENT sid="9" pm="."><plain>CCR5 signaling blockade also diminished the in vivo suppressive capacity of T(reg) in inhibiting the antitumor responses of CD8(+) T cells, in the same way as CCL5 signaling blockade </plain></SENT>
<SENT sid="10" pm="."><plain>Together, our findings establish that CCL5/CCR5 signaling recruits T(reg) to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and enhances their ability to kill antitumor CD8(+) T cells, thereby defining a novel mechanism of immune escape in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>